Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Enterprise Value data on file, last reported at -$170.4 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 82.84% year-over-year to -$170.4 million in Q1 2026; TTM through Mar 2026 was -$170.4 million, a 82.84% decrease from a year earlier, with the FY2025 full-year figure at -$178.8 million, down 83.27% from the prior year.
• Enterprise Value for Q1 2026 stood at -$170.4 million, up from -$178.8 million in the prior quarter.
• Over the last five years, Enterprise Value for IKT reached as high as -$3.2 million in Q3 2024 and fell as low as -$178.8 million in Q4 2025.
• Historically, Enterprise Value has averaged -$54.2 million across 5 years, with a median of -$26.5 million in 2022.
• Across the five-year window, Enterprise Value jumped 80.73% in 2024 and sank 2283.81% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$23.1 million in 2022, then surged by 42.51% to -$13.3 million in 2023, then sank by 636.06% to -$97.5 million in 2024, then tumbled by 83.27% to -$178.8 million in 2025, then rose by 4.7% to -$170.4 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$170.4 million in Q1 2026, -$178.8 million in Q4 2025, and -$77.3 million in Q3 2025.